FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989163710> ?p ?o ?g. }

• W2989163710 endingPage "1507" @default.
• W2989163710 startingPage "1507" @default.
• W2989163710 abstract "Apoptosis is controlled by the expression levels and interplay of pro- and anti-apoptotic BCL-2 family proteins. The specific BCL-2 inhibitor Venetoclax (VEN) showed high efficiency in BCL-2 dependent cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Despite its high efficiency in CLL and MCL, refractory disease can develop. BCL-2 mutations have been described to mediate resistance in CLL cases, however these mutations are only found in a proportion of VEN resistant cases and in a fraction of cells. In order to design alternative therapeutic strategies to overcome drug resistance, a better understanding of the mechanisms mediating resistance to VEN is necessary. VEN-resistant (VEN-R) MCL cell lines (MINO and MAVER-1) were generated by chronic exposure to increasing amounts of VEN (up to 3µM). A significant and stable upregulation of BCL-XL mRNA and protein was seen in the MINO and MAVER-1 resistant cell lines (2 and 4 fold increase in mRNA and 2.6 and 4.5 fold increase in protein, respectively). We used BH3 profiling in combination with VEN treatment for 4h to investigate the differences in anti- and pro-apoptotic signaling in parental and VEN-R cell lines. Additionally, sensitivity to VEN was restored upon shRNA-mediated knockdown of BCL-XL. These results confirmed the importance of BCL-XL upregulation in mediating resistance. Furthermore, we did not detect mutations in BCL-2 upon resistance to VEN via targeted NGS, which is in contrast to results obtained in VEN-R CLL patients (Blombery et al., Cancer Discovery 2019 and Tausch et al., Hematologica 2019). However, the results obtained by dynamic BH3-profiling (VEN treatment in combination with BH3 Profiling) suggest that increase in BCL-XL is most likely not the only alteration necessary to render cells resistant to VEN. In addition, reduced activation of pro-apoptotic proteins like BAX and BAK might contribute to resistance to VEN. In order, to investigate if VEN resistance can be overcome by drug mediated inhibition of BCL-XL we used different therapeutic approaches. Combinational treatment with the BCL-XL inhibitor A-1331852 and VEN or the single treatment with Navitoclax, a combined inhibitor of BCL-2, BCL-W and BCL-XL for 48h reduced cell viability in VEN-R MINO and MAVER-1 cell lines. Furthermore, BDA-366, a BH4 domain BCL-2 inhibitor effectively reduced the cell viability after 48h of treatment in a dose dependent manner in both parental and VEN-R cell lines. The binding of BDA-366 to the anti-apoptotic BCL-2 protein leads to a conformational change into a pro-apoptotic molecule by the exposure of the BH3 domain of the protein. Despite mediating apoptosis in a TP53-independent manner, VEN treatment in CLL has been associated with inferior outcome in the presence of TP53 aberrations. In order to address the role of TP53 dysfunction in mediating resistance to VEN, we generated p53 knock out cell lines (N=2) by CRISPR/Cas9 gene editing. This significantly decreased the sensitivity to VEN compared to p53 WT cell lines. Additionally, the sensitivity to BDA-366 was significantly reduced upon knockout of p53, suggesting an interference of p53 downstream of BCL-2. Overall, VEN resistance is mediated by a permanent increase in BCL-XL mRNA and protein level in MCL. Importantly, BDA-366, which converts the anti-apoptotic BCL-2 molecule into a BAX-like death molecule, could be a potential alternative treatment strategy for BCL-2 dependent cancers even when resistant to VEN. Despite mediating apoptosis in a p53 independent manner, VEN seems to be less effective in p53 deficient cells, underlining the importance of further investigations of treatment combinations in these groups. Disclosures Tausch: Roche: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: travel support, Speakers Bureau. Döhner:AbbVie, Agios, Amgen, Astellas, Astex, Celator, Janssen, Jazz, Seattle Genetics: Consultancy, Honoraria; AROG, Bristol Myers Squibb, Pfizer: Research Funding; Celgene, Novartis, Sunesis: Honoraria, Research Funding. Stilgenbauer:Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Hoffmann La-Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pharmacyclics: Other: Travel support; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Consultancy, Honoraria, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; GSK: Consultancy, Honoraria, Research Funding, Speakers Bureau. Schneider:Celgene: Other: travel grant." @default.
• W2989163710 created "2019-11-22" @default.
• W2989163710 creator A5019866348 @default.
• W2989163710 creator A5021537460 @default.
• W2989163710 creator A5025985392 @default.
• W2989163710 creator A5037750452 @default.
• W2989163710 creator A5048054782 @default.
• W2989163710 creator A5057187390 @default.
• W2989163710 creator A5067061874 @default.
• W2989163710 creator A5075306084 @default.
• W2989163710 creator A5088105442 @default.
• W2989163710 creator A5089395073 @default.
• W2989163710 date "2019-11-13" @default.
• W2989163710 modified "2023-09-30" @default.
• W2989163710 title "Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2" @default.
• W2989163710 doi "https://doi.org/10.1182/blood-2019-127931" @default.
• W2989163710 hasPublicationYear "2019" @default.
• W2989163710 type Work @default.
• W2989163710 sameAs 2989163710 @default.
• W2989163710 citedByCount "1" @default.
• W2989163710 countsByYear W29891637102022 @default.
• W2989163710 crossrefType "journal-article" @default.
• W2989163710 hasAuthorship W2989163710A5019866348 @default.
• W2989163710 hasAuthorship W2989163710A5021537460 @default.
• W2989163710 hasAuthorship W2989163710A5025985392 @default.
• W2989163710 hasAuthorship W2989163710A5037750452 @default.
• W2989163710 hasAuthorship W2989163710A5048054782 @default.
• W2989163710 hasAuthorship W2989163710A5057187390 @default.
• W2989163710 hasAuthorship W2989163710A5067061874 @default.
• W2989163710 hasAuthorship W2989163710A5075306084 @default.
• W2989163710 hasAuthorship W2989163710A5088105442 @default.
• W2989163710 hasAuthorship W2989163710A5089395073 @default.
• W2989163710 hasConcept C104317684 @default.
• W2989163710 hasConcept C114851261 @default.
• W2989163710 hasConcept C127561419 @default.
• W2989163710 hasConcept C173396325 @default.
• W2989163710 hasConcept C190232843 @default.
• W2989163710 hasConcept C190283241 @default.
• W2989163710 hasConcept C203014093 @default.
• W2989163710 hasConcept C2777525834 @default.
• W2989163710 hasConcept C2777938653 @default.
• W2989163710 hasConcept C2778461978 @default.
• W2989163710 hasConcept C2779338263 @default.
• W2989163710 hasConcept C2779675984 @default.
• W2989163710 hasConcept C2779878957 @default.
• W2989163710 hasConcept C2994294914 @default.
• W2989163710 hasConcept C38652104 @default.
• W2989163710 hasConcept C41008148 @default.
• W2989163710 hasConcept C502942594 @default.
• W2989163710 hasConcept C54355233 @default.
• W2989163710 hasConcept C55493867 @default.
• W2989163710 hasConcept C81885089 @default.
• W2989163710 hasConcept C86803240 @default.
• W2989163710 hasConcept C9583187 @default.
• W2989163710 hasConceptScore W2989163710C104317684 @default.
• W2989163710 hasConceptScore W2989163710C114851261 @default.
• W2989163710 hasConceptScore W2989163710C127561419 @default.
• W2989163710 hasConceptScore W2989163710C173396325 @default.
• W2989163710 hasConceptScore W2989163710C190232843 @default.
• W2989163710 hasConceptScore W2989163710C190283241 @default.
• W2989163710 hasConceptScore W2989163710C203014093 @default.
• W2989163710 hasConceptScore W2989163710C2777525834 @default.
• W2989163710 hasConceptScore W2989163710C2777938653 @default.
• W2989163710 hasConceptScore W2989163710C2778461978 @default.
• W2989163710 hasConceptScore W2989163710C2779338263 @default.
• W2989163710 hasConceptScore W2989163710C2779675984 @default.
• W2989163710 hasConceptScore W2989163710C2779878957 @default.
• W2989163710 hasConceptScore W2989163710C2994294914 @default.
• W2989163710 hasConceptScore W2989163710C38652104 @default.
• W2989163710 hasConceptScore W2989163710C41008148 @default.
• W2989163710 hasConceptScore W2989163710C502942594 @default.
• W2989163710 hasConceptScore W2989163710C54355233 @default.
• W2989163710 hasConceptScore W2989163710C55493867 @default.
• W2989163710 hasConceptScore W2989163710C81885089 @default.
• W2989163710 hasConceptScore W2989163710C86803240 @default.
• W2989163710 hasConceptScore W2989163710C9583187 @default.
• W2989163710 hasIssue "Supplement_1" @default.
• W2989163710 hasLocation W29891637101 @default.
• W2989163710 hasOpenAccess W2989163710 @default.
• W2989163710 hasPrimaryLocation W29891637101 @default.
• W2989163710 hasRelatedWork W2622044044 @default.
• W2989163710 hasRelatedWork W2626048881 @default.
• W2989163710 hasRelatedWork W2767128989 @default.
• W2989163710 hasRelatedWork W2891141671 @default.
• W2989163710 hasRelatedWork W2989163710 @default.
• W2989163710 hasRelatedWork W3037213458 @default.
• W2989163710 hasRelatedWork W3139147523 @default.
• W2989163710 hasRelatedWork W3164317351 @default.
• W2989163710 hasRelatedWork W3215197450 @default.
• W2989163710 hasRelatedWork W4225515604 @default.
• W2989163710 hasVolume "134" @default.
• W2989163710 isParatext "false" @default.
• W2989163710 isRetracted "false" @default.
• W2989163710 magId "2989163710" @default.
• W2989163710 workType "article" @default.